SecBot SecBot

INVA

Innoviva, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001080014 Biotech & Drug Discovery
$18.49 −0.54 (−2.84%)
Nov 16 4:00 PM ET · prev $19.03
Market cap
$1.3B
Small cap
Consensus
Buy
82% Buy or better · 11 analysts
Median target
$34.00
+84% · range $18.00–46.00
1 year
−15.8%
from $21.97 · Nov 17
30 days
−12.3%
from $21.08
52-week range
$18.49–24.24
at the low
Avg volume 20D
873.3K
Nov 5 spike 2.65M
Short interest
7.50M
≈10.5% of shares · +3.2%
Days to cover
12.9
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
5
analyzed by SecBot
SecBot read BEARISH 2 reports · 90 days
Balance 1 bearish · 0 bullish · 1 mixed oldest → newest, height = score
Avg score ·High conf. 1/2

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q3 2026: 21 added (0 new), 20 trimmed or exited.

  • AnalystsBULLISH

    9 of 11 rate it Buy or better. Median target $34.00 (+84%).

  • EstimatesFALLING

    Current-quarter EPS estimate $0.572 → $0.446 over 90 days. 1 up, 1 down in 30 days.

  • Short sellersSTEADY

    Short interest +3.2% to 7.50M shares. 12.9 days to cover, ≈10.5% of shares.

  • TrendDOWNTREND

    10% below its 50-day average. New closing low $18.49 on Nov 16.

  • SocialQUIET

    No Reddit mentions this week. Last mention Oct 21.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
MORGAN STANLEYADD1,721,912$36.5M
Qube Research & Technologies LtdADD1,217,937$25.8M
Invesco Ltd.ADD1,183,501$25.1M
UBS Group AGADD1,047,272$22.2M
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLCADD832,881$17.7M
AMERICAN CENTURY COMPANIES INCTRIM755,948$16.0M
MARSHALL WACE, LLPTRIM630,367$13.4M
Empowered Funds, LLCADD417,698$8.9M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

11 analysts
Buy 82% rate it Buy or better
Strong Buy4Buy5Hold1Sell1Strong Sell0
12-month targets · 5 analysts

Price is inside the target range. Median implies +84%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 5, 2026Oppenheimer
MAINTAIN
MAINTAINOutperform
Aug 7, 2026Cantor Fitzgerald
MAINTAIN
MAINTAINOverweight
Jun 22, 2026BTIG
MAINTAIN
MAINTAINBuy
Jun 1, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
May 26, 2026BTIG
REITERATE
REITERATEBuy

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Aug 20, 2026
Raifeld Pavel
Chief Executive Officer
Aug 20, 2026
TAX W/H$23.7K
Aug 20, 2026
Basso Stephen
Chief Financial Officer
Aug 20, 2026
TAX W/H$11.7K
Aug 20, 2026
Zhen Marianne
Chief Accounting Officer
Aug 20, 2026
TAX W/H$23.7K
May 20, 2026
Raifeld Pavel
Chief Executive Officer
May 20, 2026
TAX W/H$25.1K
May 20, 2026
Zhen Marianne
Chief Accounting Officer
May 20, 2026
TAX W/H$25.1K
May 20, 2026
Basso Stephen
Chief Financial Officer
May 20, 2026
TAX W/H$12.4K
May 18, 2026
Linden Josephine
Director
May 18, 2026
AWARD5,733 sh
May 18, 2026
Linden Josephine
Director
May 18, 2026
AWARD9,166 sh

Earnings setup

Estimates
$0.45
EPS estimate, this quarter
−22%
estimate change, 90 days
1↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q$0.45$0.35–$0.53-14.6%$110.8M
Next Q$0.49$0.41–$0.55-1.2%$113.1M
Current FY🔒 Fresh data, subscribers only
Next FY$2.14$1.87–$2.35-5.3%$475.3M
Reddit
Recent posts
All social signals and their track records

Short side

FINRA· Oct 30, 2026
7,495,210
shares short
+3.2%
vs prior settlement
12.9
days to cover
≈10.5%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 11, 2026 Earnings calendar
INVA Q3 2026 Earnings Scheduled · 2026-11-11
Nov 4, 2026 SEC
Innoviva Q3 2026 total revenue of $106.1M declined 1.6% YoY, missing the $115.3M consensus, as lower royalty revenue…
8-K · Impact 5/10
Oct 27, 2026 SEC
Institutional activity in Innoviva (INVA) during 2026-Q2 shows a mixed picture: 24 buyers added $5.9M in new holdings…
INST-CLUSTER · Impact 3/10
Sep 30, 2026 Inst.
MORGAN STANLEY · ADD
1,721,912 shares ($36.5M)
Sep 30, 2026 Inst.
Qube Research & Technologies · ADD
1,217,937 shares ($25.8M)
Aug 20, 2026 Insider
Raifeld Pavel surrendered for taxes 1,130 shares
Chief Executive Officer @ $21.00 ($23.7K)
Aug 20, 2026 Insider
Basso Stephen surrendered for taxes 558 shares
Chief Financial Officer @ $21.00 ($11.7K)
Aug 20, 2026 Insider
Zhen Marianne surrendered for taxes 1,127 shares
Chief Accounting Officer @ $21.00 ($23.7K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
5 drugs tracked · Drug pipeline →
Recent

SecBot reports

5 filings · 0 bullish · 1 bearish · 2 mixed · 2 neutral
All INVA filing & press-release reports (5)